N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects
Abstract N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (AcSDKP) is an endogenous peptide that has been confirmed to show excellent organ‐protective effects. Even though originally discovered as a modulator of hemotopoietic stem cells, during the recent two decades, AcSDKP has been recognized as valuable ant...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-05-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.13219 |
| _version_ | 1818865910630318080 |
|---|---|
| author | Keizo Kanasaki |
| author_facet | Keizo Kanasaki |
| author_sort | Keizo Kanasaki |
| collection | DOAJ |
| description | Abstract N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (AcSDKP) is an endogenous peptide that has been confirmed to show excellent organ‐protective effects. Even though originally discovered as a modulator of hemotopoietic stem cells, during the recent two decades, AcSDKP has been recognized as valuable antifibrotic peptide. The antifibrotic mechanism of AcSDKP is not yet clear; we have established that AcSDKP could target endothelial–mesenchymal transition program through the induction of the endothelial fibroblast growth factor receptor signaling pathway. Also, recent reports suggested the clinical significance of AcSDKP. The aim of this review was to update recent advances of the mechanistic action of AcSDKP and discuss translational research aspects. |
| first_indexed | 2024-12-19T10:55:03Z |
| format | Article |
| id | doaj.art-da9c2d759a054147b0c98c841a6936cc |
| institution | Directory Open Access Journal |
| issn | 2040-1116 2040-1124 |
| language | English |
| last_indexed | 2024-12-19T10:55:03Z |
| publishDate | 2020-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj.art-da9c2d759a054147b0c98c841a6936cc2022-12-21T20:24:50ZengWileyJournal of Diabetes Investigation2040-11162040-11242020-05-0111351652610.1111/jdi.13219N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspectsKeizo Kanasaki0Internal Medicine 1 Faculty of Medicine Shimane University Izumo JapanAbstract N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (AcSDKP) is an endogenous peptide that has been confirmed to show excellent organ‐protective effects. Even though originally discovered as a modulator of hemotopoietic stem cells, during the recent two decades, AcSDKP has been recognized as valuable antifibrotic peptide. The antifibrotic mechanism of AcSDKP is not yet clear; we have established that AcSDKP could target endothelial–mesenchymal transition program through the induction of the endothelial fibroblast growth factor receptor signaling pathway. Also, recent reports suggested the clinical significance of AcSDKP. The aim of this review was to update recent advances of the mechanistic action of AcSDKP and discuss translational research aspects.https://doi.org/10.1111/jdi.13219Angiotensin‐converting enzymeEndothelial–mesenchymal transitionFibroblast growth factor |
| spellingShingle | Keizo Kanasaki N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects Journal of Diabetes Investigation Angiotensin‐converting enzyme Endothelial–mesenchymal transition Fibroblast growth factor |
| title | N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects |
| title_full | N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects |
| title_fullStr | N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects |
| title_full_unstemmed | N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects |
| title_short | N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects |
| title_sort | n acetyl seryl aspartyl lysyl proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes an update and translational aspects |
| topic | Angiotensin‐converting enzyme Endothelial–mesenchymal transition Fibroblast growth factor |
| url | https://doi.org/10.1111/jdi.13219 |
| work_keys_str_mv | AT keizokanasaki nacetylserylaspartyllysylprolineisavaluableendogenousantifibroticpeptideforkidneyfibrosisindiabetesanupdateandtranslationalaspects |